MARSHALL WACE, LLP

Position in RLMD — Relmada Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in RLMD

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$31,191,976

+$15,785,910 QoQ

Shares Held

4,481,606

+40.5% QoQ

Ownership

4.27%

of shares outstanding

% of Portfolio

0.04%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Sep 2022

9 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,766,756,129 across 280 Biotechnology names. RLMD ranks #21 (1.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$31,191,976	4,481,606	+40.5%	Shares	Other	2026-05-15
2025-12-31	$15,406,066	3,189,662	+1072.4%	Shares	Other	2026-02-13
2025-09-30	$546,825	272,053	+76.0%	Shares	Other	2025-11-13
2025-06-30	$92,740	154,568	+205.7%	Shares	Other	2025-08-13
2024-09-30	$163,845	50,570	-67.7%	Shares	Other	2024-11-14
2024-06-30	$469,857	156,619	-24.7%	Shares	Other	2024-08-14
2024-03-31	$966,595	207,870	+35.4%	Shares	Other	2024-05-15
2023-12-31	$635,593	153,525	+59.5%	Shares	Other	2024-02-14
2022-09-30	$3,563,322	96,254	—	Shares	Other	2022-11-14
No filing history on record for this holder in this stock.